Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Shares Sold by LSV Asset Management

LSV Asset Management decreased its stake in shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) by 4.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 391,758 shares of the specialty pharmaceutical company’s stock after selling 17,000 shares during the period. LSV Asset Management owned 3.02% of Eagle Pharmaceuticals worth $2,049,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of EGRX. Headlands Technologies LLC increased its holdings in shares of Eagle Pharmaceuticals by 263.4% during the 3rd quarter. Headlands Technologies LLC now owns 2,326 shares of the specialty pharmaceutical company’s stock worth $37,000 after buying an additional 1,686 shares during the last quarter. DGS Capital Management LLC acquired a new stake in Eagle Pharmaceuticals during the fourth quarter worth about $60,000. Strs Ohio purchased a new position in shares of Eagle Pharmaceuticals in the 3rd quarter worth about $145,000. Connors Investor Services Inc. lifted its stake in shares of Eagle Pharmaceuticals by 24.8% in the 3rd quarter. Connors Investor Services Inc. now owns 12,566 shares of the specialty pharmaceutical company’s stock valued at $198,000 after purchasing an additional 2,500 shares in the last quarter. Finally, Los Angeles Capital Management LLC lifted its stake in shares of Eagle Pharmaceuticals by 68.1% in the 4th quarter. Los Angeles Capital Management LLC now owns 91,262 shares of the specialty pharmaceutical company’s stock valued at $477,000 after purchasing an additional 36,982 shares in the last quarter. Hedge funds and other institutional investors own 85.36% of the company’s stock.

Eagle Pharmaceuticals Stock Performance

EGRX opened at $4.66 on Friday. The company has a market cap of $60.52 million, a PE ratio of 3.95 and a beta of 0.46. Eagle Pharmaceuticals, Inc. has a 1 year low of $3.95 and a 1 year high of $25.29. The firm has a 50 day moving average price of $5.09 and a 200 day moving average price of $6.38.

Eagle Pharmaceuticals Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.